Most peptide research focuses on what a compound does inside the body. A newer line of inquiry asks a different question: how do you get the peptide where it needs to go, keep it stable, and release it at a useful rate? A study published in 3 Biotech tackled that question specifically for BPC-157, a short peptide sequence derived from a gastric protein that has attracted growing interest in regenerative research.
The team, led by Arunim and colleagues, fabricated what they called a CH/BPC composite hydrogel, meaning a gel built from chitosan (a natural polymer derived from shellfish shells) with BPC-157 loaded inside. Their goal was not to test what the peptide does biologically in this instance, but to characterize the physical and chemical properties of the gel itself, and to determine whether it could hold the peptide reliably and release it in a controlled way.
The findings, published in 2026, suggest this type of carrier system may have real merit. The gel scored well on several practical benchmarks: encapsulation efficiency, release rate, structural integrity, and safety markers. Each of those terms has a specific meaning in materials science, and unpacking them helps explain why the research community finds this approach worth pursuing.
Why peptide delivery is a real problem
Peptides are fragile. They can degrade before reaching a target site, disperse unevenly through tissue, or require repeated administration to maintain a useful concentration. Researchers have long worked on carrier systems that address these limitations, and hydrogels are one of the more promising options in the current literature.
A hydrogel is a three-dimensional polymer network that holds large amounts of water while maintaining a semi-solid structure. Think of a firm gelatin dessert at the molecular scale. The porous structure allows small molecules like peptides to sit inside the network and diffuse outward gradually, rather than releasing all at once. That controlled release profile is what makes hydrogels attractive for sustained local delivery in biomedical settings.
Chitosan was chosen as the backbone material in this study for several reasons the researchers note: it is biocompatible, biodegradable, and has natural antibacterial properties of its own. Combining it with BPC-157 was intended to produce a material whose properties exceed what either component offers alone.
How the gel was built and confirmed
The fabrication process involved blending chitosan with BPC-157 under controlled conditions to encourage the peptide to integrate into the polymer matrix rather than simply sitting loosely inside it. To confirm that integration actually happened, the researchers used Fourier-transform infrared spectroscopy, a technique that identifies chemical bonds by how they absorb infrared light.
The FTIR data showed hydrogen bonding between the BPC-157 peptide and the chitosan backbone. Hydrogen bonds are relatively gentle molecular attractions, but they are enough to anchor the peptide within the gel structure rather than letting it pool freely. This matters because anchored peptide releases more predictably than peptide that is simply trapped by pore size.
The team also used scanning electron microscopy and transmission electron microscopy to image the gel at very high magnification. Both techniques confirmed a porous internal structure, which is exactly what you want in a controlled-release matrix. Larger or more connected pores would allow faster diffusion; a denser network would slow it. The images gave the researchers a way to link structural features to the release behavior they measured later.
Encapsulation and release numbers
One of the most practically important findings in the study was the encapsulation efficiency: 98.9 percent, plus or minus 0.8 percent. That figure means that out of all the BPC-157 added during fabrication, essentially all of it ended up incorporated into the gel rather than lost to the surrounding solution. For a delivery system, this matters enormously because wasted peptide during loading translates directly to dose uncertainty during use.
The release profile was measured over 24 hours. Within that window, the gel released 81.2 percent of its encapsulated BPC-157, plus or minus 2.9 percent. That combination, very high retention during storage and substantial release within a day, describes a system that holds the peptide tightly until it is placed in an aqueous environment resembling tissue, then allows a majority of the payload to diffuse out over a clinically relevant timeframe.
The remaining roughly 19 percent that stayed in the gel at 24 hours suggests the system is not simply dumping its contents immediately, which would defeat the purpose of using a hydrogel in the first place. Early data points at a release curve that starts briskly and then slows, a profile the researchers describe as controlled.
Physical properties that matter for use
Beyond the peptide chemistry, the researchers measured several physical properties that determine whether a hydrogel is practical in biomedical settings. Three stood out in the abstract.
First, injectability. A gel that can be drawn into a syringe and pushed through a needle without breaking down has obvious advantages over one that must be surgically implanted. The CH/BPC hydrogel was confirmed to be injectable, which the literature identifies as a key requirement for minimally invasive delivery approaches.
Second, self-healing capability. When the gel structure is disrupted by mechanical force, such as passing through a needle, a self-healing material can reform its network after the stress is removed. The researchers confirmed this property, which means the gel could recover its structure once placed at the target site.
Third, adhesiveness. A hydrogel that sticks to tissue surfaces stays in place longer than one that flows away. The study confirmed adhesive behavior, which would help retain the gel and its peptide payload at a localized area rather than dispersing systemically.
Antibacterial activity and blood safety
Two additional test categories addressed safety and functional range. The antibacterial tests measured how well the gel inhibited bacterial growth. Against two separate bacterial strains, the CH/BPC hydrogel achieved inhibition rates of 45.9 percent and 65.0 percent respectively. The researchers attribute this activity to the chitosan component, which is known independently to disrupt bacterial membranes, possibly enhanced by the presence of the peptide. Whether BPC-157 contributes directly to the antibacterial effect or whether chitosan is doing most of the work is not resolved by this study, but the combined material showed meaningful inhibition.
The blood safety test measured hemolysis, meaning the degree to which the material causes red blood cells to rupture. A hemolysis rate below 5 percent is the standard threshold used in biomedical materials research to indicate acceptable compatibility with blood. The CH/BPC hydrogel came in below that threshold, which the researchers describe as indicating acceptable hemocompatibility. This matters for any material that might contact the bloodstream, either directly or through absorption from a wound site.
Together, the antibacterial and hemolysis results suggest the material is functional and not acutely harmful to blood cells, two properties the literature treats as foundational requirements before a material moves further along the development pipeline.
What this means for BPC-157 research
This study does not test what BPC-157 does biologically. It tests how to carry it. That distinction is important. The broader literature on BPC-157 has largely used solution-based delivery, either injected or given orally in animal models, and a substantial portion of that research focuses on its effects in gastrointestinal, musculoskeletal, and wound-healing contexts. What has been less studied is localized, sustained delivery of the peptide using a matrix that stays in place.
The CH/BPC hydrogel work opens a methodological door. If future studies use this type of carrier in animal or cell models, they gain a tool that can deliver a defined peptide dose to a defined site over a defined timeframe. That level of control is difficult to achieve with direct injection, where the peptide disperses quickly and concentration at any one location drops rapidly.
The researchers conclude that the hydrogel possesses desirable physicochemical and antibacterial characteristics and highlight its potential as a multifunctional material for future biomedical applications. The language is appropriately cautious: this is a characterization study, not a clinical or even a full biological efficacy study. But as a proof-of-concept for BPC-157 delivery engineering, the numbers presented are encouraging enough to justify the next stage of investigation.
